PTO/SB/26 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

er the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A PRIOR PATENT

Docket Number (Optional)

98-164-A24

In re Application of: Wolff Application No.: 10/614,460		
Filed: July 7, 2003		
For: Sustained Release Ranolazine Formulations		
The owner*, C.V. Therapeutics, Inc. of 100	percent interest in the instan	t application hereby
disclaims, except as provided below, the terminal part of the stat which would extend beyond the expiration date of the full statu shortened by any terminal disclaimer, of prior Patent No. 6,303 so granted on the instant application shall be enforceable only commonly owned. This agreement runs with any patent granted its successors or assigns.	tory term defined in 35 U.S.C. 154 a 3,607	and 173, as presently grees that any patent d the prior patent are
In making the above disclaimer, the owner does not disapplication that would extend to the expiration date of the full sprior patent, as presently shortened by any terminal disclaimer maintenance fee, is held unenforceable, is found invalid by a whole or terminally disclaimed under 37 CFR 1.321, has all claims in any manner terminated prior to the expiration of its ful disclaimer.	statutory term as defined in 35 U.S.C er, in the event that it later: expires court of competent jurisdiction, is sta ms canceled by a reexamination cert	2. 154 and 173 of the s for failure to pay a atutorily disclaimed in ificate, is reissued, or
Check either box 1 or 2 below, if appropriate.		
1. XX For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.		
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.		
2. The undersigned is an attorney or agent of record.	/a 1 /aux 6	/22/04
	Signature	Date
04 CCHAU1 00000156 501789 10614460	Louis G. Lange	
55.00 DA Typed or printed name (650) 384-8501		me
	Telephone Number	
Terminal disclaimer fee under 37 CFR 1.20(d) included.		
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.		
*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.		

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

07/01/20 01 FC:28